agilon Health (AGL) Could Be 30% Undervalued After Springfield Clinic Expansion
Why the Springfield Clinic expansion matters for agilon health
agilon health (AGL) is back in focus after expanding its partnership with Springfield Clinic in Illinois, adding more seniors to its value-based care footprint through a larger Accountable Care Organization arrangement.
The move extends an existing long-term relationship that already covers Medicare Advantage patients and now aims to bring roughly 21,000 additional Traditional Medicare beneficiaries into agilon’s Senior Health Connect ACO structure.
Against that backdrop, agilon health’s share price has cooled recently, with a 1-day share price return of 1.74% down, a 7-day move of 10.01% lower and a 30-day decline of 15.55%. This has contributed to a 90-day share price drop of 30.06%, even as the year-to-date share price return is very large at roughly 7.5x. The 1-year total shareholder return of 203.5% contrasts sharply with a 3-year total shareholder return decline of 81.77% and a 5-year total shareholder return fall of 88%.
Scan how agilon health compares with other value-focused healthcare names by reviewing the hand picked 31 high quality undervalued stocks now shaping investor watchlists.
After a sharp run followed by a steep pullback, agilon health now sits at a crossroads. Is most of the easy upside already gone, or does the recent slide reset the valuation story in your favor?
Most Popular Narrative: 30% Undervalued
Analysts following agilon health see a gap between the last close at $78.15 and their narrative fair value of $110.92, and they link that gap to how the business scales its senior care model over time rather than short term share price swings.
Expansion of clinical pathways, successful scaling of chronic disease management programs, and strong PCP and patient retention reinforce agilon health's operational leverage, paving the way for durable earnings growth, enhanced gross margin, and improved operating cash flow as the platform scales.
See why 10 investors see agilon health as 30% undervalued.
Result: Fair Value of $110.92 (UNDERVALUED)
Still, agilon health faces pressure if risk adjustment revenue continues to lag, and if payer negotiations tied to concentrated partners lead to tougher contract terms.
Find out about the key risks to this agilon health narrative.
Next Steps
Mixed signals or early innings for agilon health: either way you should move quickly, test the narrative against the numbers, and weigh the 4 key rewards and 1 important warning sign.
Looking for more agilon health style opportunities?
If you stop at agilon health, you risk missing other ideas that could fit your plan just as well or even complement your current positions.
- Chase potential upside in smaller companies that already show financial strength by scanning the 9 elite penny stocks with strong financials.
- Zero in on companies that combine quality fundamentals with appealing valuations by checking the 17 high quality undiscovered gems.
- Prioritize resilience and capital protection by reviewing the 32 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com